search

Active clinical trials for "Sarcoma"

Results 1431-1440 of 1445

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Epithelioid Sarcoma (Ex-US Only)Spindle Cell Sarcoma18 more

Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.

No longer available22 enrollment criteria

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Ewing Sarcoma

Despite improvements in outcomes for patients with localized Ewing sarcoma, patients with relapsed metastatic Ewing sarcoma continue to have poor outcomes with current chemotherapy options. A large body of preclinical data supports a role for IGF-1R inhibition in the treatment of Ewing sarcoma. More recently, clinical trials of IGF-1R monoclonal antibodies have demonstrated single- agent activity in patients with relapsed Ewing sarcoma. Ganitumab (AMG 479) is a fully human monoclonal antibody directed against IGF-1R. We are proposing this single-agent expanded access IND to provide our patient the opportunity to benefit from this treatment after having developed progressive disease after multiple lines of prior therapy.

No longer available9 enrollment criteria

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Sarcoma

Compassionate use of aldoxorubicin in sarcoma patients who have failed prior chemotherapy.

No longer available23 enrollment criteria

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

GlioblastomaSquamous Cell Carcinoma14 more

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.

Available2 enrollment criteria

SARC021C: A Continuation Study of TH-CR-406/SARC021

Soft Tissue Sarcoma

SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.

No longer available6 enrollment criteria

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

Uterine Sarcoma

Single patient treatment with everolimus.

Available0 enrollment criteria

Clinical Evaluation for Sarcoma Originated From Bone

SensitivitySpecificity2 more

Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating primary sarcoma originated from bone treated with chemotherapy or targeted therapy, which did not have the definition of measurement methods either. This study evaluates whether clinical imaging findings of sarcoma after preoperative chemotherapy correlate with tumor responses by pathological evaluation by Huvos classifications and develops reliable, quantitative, clinical response criteria.

Unknown status8 enrollment criteria

Sarcoma Database at KFSH&RC

Sarcoma Database

Sarcoma Database

Unknown status2 enrollment criteria

Detection of Circulating Tumor Cells in Patients With Sarcomas

LeiomyosarcomaPleomorphic Liposarcoma2 more

The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of cancer, due the fact that it affects children and young people. The diagnosis and treatment are difficult, considering the diversity and rarity of this disease. In addition, on average, more than 50% of patients with high-grade sarcoma present tumor relapse and distant recurrence is considered the main cause of death. The presence of Circulating Tumor Cells (CTCs) in the blood of patients with sarcoma may be an early marker of tumor invasion, because it is known that the CTCs circulate in the blood for months or years before the development of metastases. The CTCs can be used to monitor the response of the tumor to treatment, in order to match time, dose, and type of therapy. Objectives: collect blood from patients with different types of sarcoma (leiomyosarcoma, synovial sarcoma, pleomorphic sarcoma and liposarcoma) in order to isolate and quantify CTCs. The investigators also have an intention to identify genes of resistance to treatment in these cells.

Unknown status6 enrollment criteria

Validation of a Genetic Signature to Predict the Development of Sarcomas

Genetic Signature in Development of Sarcomas

The aim of the SARI study was to describe biomarkers of predisposition to the development of sarcomas in irradiated territory. This study included 120 patients with sarcoma in irradiated territory and 240 patients who had been treated with radiotherapy for more than 5 years and had not developed sarcoma. Following the sequencing of the exomes of all these patients, the SARI study made it possible to highlight a genetic signature from 11 genes, predictive of the appearance of a sarcoma after a first radiotherapy. This signature is the subject of a patent (BFF 170286 / VF, filed on June 22, 2017). A final validation step with samples that have not been used to optimize this signature is now required. Moreover, it is now necessary to validate if this signature is specific to the predisposition to the development of radiation-induced sarcomas only or if this signature is also valid for the predisposition to the development of all sarcomas, even primary ones. The objective of the PREDISARC study is to evaluate the specificity of this genetic signature (11 genes) with the appearance of sarcomas in irradiated territory compared to a population without sarcoma that has been treated with radiotherapy.

Unknown status10 enrollment criteria
1...143144145

Need Help? Contact our team!


We'll reach out to this number within 24 hrs